MBOT, US59503A2042

Microbot Medical stock targets 12 sales territories by year-end

Published on 10/05/2026 at 17:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Microbot Medical stock is tied to a commercial plan that targets 12 sales territories by year-end. Q2 revenue grew more than 100 percent over Q1, while MBOT traded at USD 1.13 on October 5.

MBOT, US59503A2042, Illustration mit AI erstellt.

Microbot Medical stock (ISIN US59503A2042) was trading at USD 1.13 on Nasdaq on October 5, 2026, at 11:52 a.m. ET, down 2.59 percent from the prior close. The company is expanding its commercial footprint for the LIBERTY endovascular robotic system, with a plan to reach 12 U.S. sales territories by year-end, according to Microbot Medical in its September 25, 2026 release.

California expands the sales footprint

The September 25 update identified the company's first California customer and described expansion in North Carolina. Microbot Medical also said it had hired three additional Area Sales Managers and one Regional Sales Director to support new territories, according to Microbot Medical.

The commercial hurdle is hospital purchasing. The company described the Value Analysis Committee process as taking four to six months based on its experience, making the pace of committee approvals an important link between new territories and recurring procedure volume.

Quarterly revenue more than doubled

Microbot Medical reported that second-quarter 2026 revenue increased by more than 100 percent from the first quarter, while customer counts also grew by more than 100 percent. The comparison covers the quarters ended March 31 and June 30, 2026, and followed the full market release of LIBERTY in April, according to Microbot Medical.

The manufacturing plan adds another measurable checkpoint. Microbot Medical said a second manufacturing line and process improvements are intended to produce positive gross margins in 2027, while possible expansion into Asia and the Middle East remains part of its commercial strategy.

Analyst targets remain far above MBOT

StockAnalysis lists a Strong Buy consensus from 3 analysts and an average price target of USD 6.33. Against the USD 1.13 Nasdaq price on October 5, 2026, that target lies 460.18 percent above the price.

The range of opinion is visible in a separate analyst action. Markets Insider reported on September 25, 2026, that Lucid Capital lowered its price target from USD 4 to USD 3 while keeping a Buy rating. The contrasting targets put hospital adoption and procedure growth at the center of the valuation debate.

MBOT trades near its yearly low

MBOT's USD 1.13 intraday price on Nasdaq on October 5, 2026, sat between the session low of USD 1.12 and the session high of USD 1.16. The 52-week range was USD 1.12 to USD 3.46, while the market capitalization was USD 51.5 million and volume was 442,278 shares.